Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells
- PMID: 8575863
- DOI: 10.1002/(SICI)1097-0215(19960126)65:3<389::AID-IJC19>3.0.CO;2-5
Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells
Abstract
Pharmacologically active in vivo doses of P-glycoprotein (Pgp) blockers, specifically verapamil, Cremophor EL and PSC833 cause toxicity in addition to that from the concomitantly used cancer chemotherapeutic drugs. It was shown before that these blockers cause different types of toxicities in vivo. We found that these 3 chemically distinct Pgp blockers exert different biophysical effects on the membranes of L1210 MDR cells. They also affect the general metabolism of these cells differently, but all block affinity labeling of Pgp. We could also show that the combination of suboptimal doses of these blockers can restore the uptake of the Pgp substrate rhodamine 123 into L1210MDR, 3T3MDR and KB-VI cells and can reduce the survival rate of these cells when treated in combination with daunorubicin. Our results suggest that the combination of suboptimal doses of these Pgp blockers may be advantageous in clinical practice.
Similar articles
-
Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.Cancer Lett. 2001 Jun 26;167(2):157-62. doi: 10.1016/s0304-3835(01)00488-8. Cancer Lett. 2001. PMID: 11369136
-
Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).Anticancer Res. 1999 Mar-Apr;19(2A):1053-64. Anticancer Res. 1999. PMID: 10368654
-
[Pharmacological control of P-glycoprotein expression].Bull Cancer. 1994 May;81(5):386-91. Bull Cancer. 1994. PMID: 7749215 French.
-
Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.Anticancer Drugs. 1993 Dec;4(6):605-15. Anticancer Drugs. 1993. PMID: 7905300
-
MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.Hematol Oncol Clin North Am. 1995 Apr;9(2):319-36. Hematol Oncol Clin North Am. 1995. PMID: 7642466 Review.
Cited by
-
Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers.Antimicrob Agents Chemother. 2001 Nov;45(11):3171-4. doi: 10.1128/AAC.45.11.3171-3174.2001. Antimicrob Agents Chemother. 2001. PMID: 11600373 Free PMC article.
-
Effect of pluronic P85 on ATPase activity of drug efflux transporters.Pharm Res. 2004 Dec;21(12):2226-33. doi: 10.1007/s11095-004-7675-5. Pharm Res. 2004. PMID: 15648254 Free PMC article.
-
Role of formulation vehicles in taxane pharmacology.Invest New Drugs. 2001 May;19(2):125-41. doi: 10.1023/a:1010618632738. Invest New Drugs. 2001. PMID: 11392447 Review.
-
Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming multidrug resistance in tumor cell lines simultaneously.Pharm Res. 2010 Aug;27(8):1498-511. doi: 10.1007/s11095-010-0147-1. Epub 2010 Apr 23. Pharm Res. 2010. PMID: 20411408
-
Molecular Events as Targets of Anticancer Drug Therapy.Pathol Oncol Res. 1997;3(2):147-158. doi: 10.1007/BF02907812. Pathol Oncol Res. 1997. PMID: 11173644
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous